Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

Founded in Boston in 2004, RA Capital is an investment firm specializing in life sciences and drug development. Its team, with backgrounds in biology, chemistry, medicine, and industry experience, invests in early-stage companies with promising technologies and products across healthcare and life science sectors.

SOSV is a global venture capital firm that supports early-stage startups through active, founder-first development programs. Its flagship initiatives HAX and IndieBio provide facilities, engineering resources, services, and laboratory equipment to accelerate product development and prepare companies for subsequent funding rounds. SOSV focuses on deep technology across health, environmental, and cross-border software sectors, aiming to solve human and planetary health challenges. In addition to providing capital, the firm emphasizes intensive programmatic support to help portfolio companies move quickly from seed toward growth, including customer acquisition and scale. The firm operates globally with a bias toward startups targeting rapid international expansion, especially in Asia, and tends to back a small cohort of high-potential companies to accelerate their progress and attract leading investors.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, manufacture, and sale of medicines. It operates facilities in the United States, Puerto Rico, and many other countries, with products sold in about 135 countries. The company focuses on therapies in neuroscience, cardiometabolic, cancer, and immunology, and also conducts research in animal health and animal agriculture. Lilly supports patient outcomes and education through a philanthropic foundation that funds programs in underserved communities, including STEM education in Indianapolis.

Novo Holdings is a Danish holding and investment firm managing the assets of the Novo Nordisk Foundation. Established in 1999, it invests globally in life science companies at all stages of development, with a portfolio also including equities, bonds, real estate, and infrastructure.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with offices in the United States, India and China. It makes investments across technology and healthcare startups at multiple stages, from seed to growth, including software, cloud, data, internet services, fintech, AI, e-commerce, and enterprise technology, as well as healthcare information technology, life sciences, medical devices, and biopharma. It also considers energy technology and infrastructure opportunities, such as solar, batteries and smart grids. The firm pursues a global approach, with activity in the United States, Asia and other regions, and supports companies through rounds of financing ranging from small to sizable investments as they scale. NEA focuses on building portfolios in software, IT services, consumer technology, and healthcare technology, backing ambitious entrepreneurs across sectors and geographies.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. Based in Pasadena, California, it provides long-term strategic capital to innovative life sciences and technology companies developing breakthrough therapies, diagnostics, and platforms across biopharma, digital health, agrifoodtech, agtech, and related healthcare fields. Established in 1996, the firm invests across seed, early, and growth stages and leverages its deep industry knowledge, extensive investor networks, and scientific advisory resources to support portfolio companies. The unit also pursues opportunities at the intersection of real estate, life sciences, and technology, reflecting its parent company's sector focus and integrated ecosystem approach. It aims to help entities advance human health by partnering with founders to scale transformative technologies.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.

Founded in 1986, Morningside Group is a venture capital firm based in the greater Boston area. It invests in companies with innovative science and technology across life sciences, digital health, AI, materials, and technology sectors.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that focuses on biotechnology and life sciences companies in the United States. The firm seeks to invest in pharmaceutical and biotechnology ventures, including oncology and other healthcare technologies, with a goal of supporting entrepreneurs in turning ideas into developed therapies. It emphasizes collaboration with ambitious partners and aims to advance biotech innovation and important new therapies by providing capital and advisory support. The organization also operates as a registered investment adviser, offering investment advisory services to guide portfolio companies through growth and development.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments in technology and healthcare, with interests spanning information technology, life sciences and related sectors in the United States. The firm has supported a broad portfolio of companies, including Apple, Intel, Illumina, DoubleClick, Athenahealth, Gilead Sciences, Nest, SlideShare and Tudou. Venrock emphasizes long-term partnerships with entrepreneurs, combining hands-on venture support with rigorous data analysis to help startups grow into enduring companies.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages of company development, with emphasis on discovery and development of novel therapeutics. It leverages deep investment, operating, and scientific expertise to take a hands-on approach to building companies. Since its inception, more than 65 portfolio companies have achieved successful acquisitions or IPOs, reflecting its track record of helping startups advance therapies, devices, and life sciences ventures. The firm focuses on medical devices, biotechnology, pharmaceuticals, and life sciences, including oncology. It aims to support early-stage and growth-stage companies across the United States, Canada, and Europe, enabling development across the healthcare continuum.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, affiliated with Fidelity Investments. It backs technology and life sciences entrepreneurs across the Americas, Europe, and Asia, drawing on Fidelity’s experience in funding early-stage companies. The firm focuses on sectors such as healthcare IT, medtech, therapeutics, fintech, frontier technologies, crypto, and broader information technology and technology-enabled services. With a global network of regional teams and affiliated funds, F-Prime provides domain expertise, strategic guidance, and industry connections to help founders build durable companies. It operates with a long-term, founder-centric approach, emphasizing value creation rather than external fundraising pressures.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a technology-focused capital provider based in Philadelphia, founded in 1982 to advance the region's technology community. The organization funds and supports technology companies across Pennsylvania, especially in information technology, health, and physical sciences, investing substantial capital in early-stage and established ventures. It has invested over 170 million dollars in more than 1,750 regional technology companies and has launched university-industry partnerships to translate scientific discoveries into commercial products, while seeding regional initiatives that strengthen the entrepreneurial ecosystem and create jobs.

Founded in 2000, General Catalyst is a venture capital firm specializing in early-stage and growth equity investments. It focuses on accelerating ideas, careers, and companies towards success by providing ongoing momentum and mentorship based on deep experience.

Right Side Capital Management is a San Francisco based venture capital firm that backs early-stage technology startups with a focus on pre-seed rounds. It makes about 75-100 investments per year in capital-efficient companies seeking to reach product-market fit, typically in rounds of 50k to 500k and pre-money valuations of 1M to 3M. The firm pursues opportunities outside the San Francisco Bay Area and New York City, and it invests across the United States, Canada, Israel, Australia, New Zealand, and Western Europe, with a portfolio spanning many states and roughly two hundred prior investments since its early operations.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.

Founded in 1849, Pfizer is a global pharmaceutical company dedicated to discovering and developing safe, effective, and affordable medicines. With a broad portfolio across various therapeutic areas, Pfizer focuses on wellness, prevention, treatment, and cures for diseases, including investments in emerging technologies to shape the future of healthcare.

Sequoia Capital Israel is a venture capital firm that backs startups and growth companies across seed to late-stage rounds, with a focus on Israel. It invests across sectors including fintech, financial services, internet, mobile, technology, and healthcare, spanning banking, payments, advertising, ecommerce, data, security, software, and related enabling tech. Typical commitments range from 100,000 to 1 million in seed, 1 to 10 million in early venture, and 10 to 100 million in growth rounds. The firm is based in Tel Aviv and operates as part of Sequoia Capital's global network.

Andreessen Horowitz is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz and based in Menlo Park, California. It funds startups across the entire lifecycle, from seed to growth, with a broad focus on software and technology-enabled businesses. The firm backs companies in software, cloud infrastructure, digital platforms, data storage, and mobile and Internet services, as well as sectors at the intersection of technology with life sciences, such as bio healthcare and computational medicine. Its investments span artificial intelligence, fintech, consumer and enterprise software, crypto and blockchain, cybersecurity, and related infrastructure. Through strategic guidance and a hands-on approach, the firm aims to help portfolio companies scale and innovate.

Mission BioCapital is a life science venture capital firm investing in early-stage companies within the biotechnology sector. Founded in Cambridge, Massachusetts in 2009, the company is known for its experienced leadership team and deep support provided to portfolio companies.

SV Health Investors is a venture capital and growth equity firm focused on healthcare and life sciences. Headquartered in the United States with offices in Boston, San Francisco and London, the firm supports entrepreneurs who develop breakthrough medicines, devices and related technologies. It manages multiple private healthcare funds and has a 20-year track record in the US and Europe, investing across North America and Western Europe to advance innovative treatments and diagnostics. SV Health Investors aims to transform healthcare by backing early-stage and growth opportunities in biotechnology, medical devices and related sectors.

Kurma Partners is a Paris-based investment firm founded in 2009 that concentrates on financing innovation in healthcare and biotechnology across Europe. It targets early-stage and development capital for companies in life sciences, biotechnology, digital health, and related fields, and emphasizes collaborations with research institutes and hospitals to advance therapies and medical technologies from concept to clinical development. The firm operates as a specialist investor in Europe, supporting ventures that bridge scientific discovery and patient impact through equity investments and strategic guidance.

Founded in 2014, Gaingels is a venture investment syndicate dedicated to supporting the LGBT+ community. It invests globally in companies led by LGBT+ founders or C-suite executives at all stages of growth, focusing on inclusivity and positive social change.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

Founded in 2001 and based in Zug, Switzerland, HBM Healthcare Investments is a venture capital firm focusing on the healthcare sector. It invests globally in mature emerging companies primarily in biotechnology/human medicine, diagnostics, and medical technology sectors.

Founded in Singapore in 2017, Antler is an early-stage venture capital firm that invests globally. It focuses on backing exceptional founders from day one, offering a global community network of co-founders, talent, advisors, expansion support, and capital across various sectors such as technology, healthcare, finance, consumer goods, and more.

Korea Investment Partners is a Seoul-based venture capital and private equity firm with more than three decades of investing experience. It operates globally from its Seoul headquarters with offices in Shanghai, Beijing and Sunnyvale, and manages multiple funds that invest across a broad spectrum of sectors including business-to-business services, media, healthcare, information technology, manufacturing, life sciences, oncology, mobile and gaming, augmented reality, industrials, real estate technology, mortgage technology, advertising technology, advanced manufacturing, the Internet of Things and mobility technologies. The firm has backed notable companies such as Kakao, Naver, YG Entertainment, Osstem Implant, Bodyfriend and Didi Chuxing, reflecting its emphasis on innovative entrepreneurs and large-scale opportunities.

Casdin Capital is a New York‑based investment firm founded in 2012 by Eli Casdin. The firm specializes in fundamental research and long‑short equity strategies focused on the life sciences and healthcare sectors, including oncology, digital health, and agtech. In addition to its public‑market fund, Casdin Capital invests in early‑stage to late‑stage private companies within these industries. It operates as a Registered Investment Adviser and, as of October 2020, managed approximately $2.2 billion in assets.

Vivo Capital is a global healthcare investment firm based in Palo Alto with offices in Asia. Founded in 1996, it focuses on investing in and building high-quality companies in the United States and China. The firm engages across multiple strategies, including growth equity, private equity (buyouts), venture capital, and public equity, and invests in biopharmaceuticals, medical devices, and healthcare services. With about 25 years of operation, it manages approximately 5.8 billion in assets and has participated in over 290 public and private companies worldwide. The team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts, reflecting a hands-on approach to helping portfolio companies scale in major healthcare markets.

Established in 1973, Johnson & Johnson Innovation facilitates early-stage innovation through strategic partnerships. It connects potential collaborators with resources to advance transformative science and technology across pharmaceuticals, medical devices, and consumer healthcare sectors.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

IP Group is a London-based corporate firm that provides financial, strategic, and commercial expertise to clients internationally. Founded in 2001, the company focuses on creating value through the commercialisation of intellectual property derived from research-intensive institutions. It manages the end-to-end process of identifying viable IP, developing or partnering to build value, and establishing commercial arrangements that translate scientific advances into practical products and businesses. IP Group combines industry insight and financial experience to support science- and technology-based ventures, offering capital as well as strategic guidance to help companies grow and accelerate the impact of research. Its work spans clean technology, life sciences, and other deep technology sectors, with a track record of backing and developing ventures that aim to deliver tangible societal and economic outcomes.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates its investments in life sciences, diagnostics, therapeutics, digital health, and related technologies, including AI and machine learning applications in biotech and medical fields, as well as environmental and other emerging technologies. It seeks to back early- and growth-stage companies that advance biomedical research, diagnostics, medical devices, and technology-enabled health solutions. The firm operates as a registered investment adviser and emphasizes building a better tomorrow through science-driven investing. It focuses on strategy, value creation, and supporting companies at the intersection of life sciences and technology, aiming to accelerate innovations that improve health outcomes.

Legend Capital is a Beijing-based venture capital firm and subsidiary of Legend Holdings. Founded in 2001, it focuses on early-stage and growth investments in technology-driven sectors with operations anchored in China and related markets. The firm backs companies in IT, internet applications and services, outsourcing, IC design and key components, as well as sectors such as telecommunications, media, healthcare, consumer and intelligent manufacturing. It manages multiple funds and actively supports portfolio companies with business development, market positioning and access to Chinese markets to create value. Legend Capital aims to back high-growth ventures and build lasting value in China's venture capital ecosystem.

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies and create long-term value. Its activities span sectors such as healthcare, logistics, software, energy, manufacturing, enterprise IT, and life sciences, with a focus on supporting early-stage and growth opportunities in the United States and beyond.

Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, specializing in life sciences and biotechnology. It supports the translation of high-impact scientific discoveries into medicines for patients through a seed-led venture creation strategy that identifies and builds scalable companies with strong scientific foundations. The firm combines experienced scientists and career venture capitalists to select compelling opportunities and realize value, emphasizing early-stage investments in life sciences and technology. Atlas Venture also maintains a multi-disciplinary team able to advance startups from concept to clinical development and commercial viability.

Takeda Ventures is a strategic investment arm of Takeda Pharmaceutical Company Limited, focusing on direct and fund-of-fund investments in healthcare and life sciences sectors. It specializes in seed to mid-stage investments, with a primary focus on therapeutics, regenerative medicines, RNA/DNA modulation, and innovative protein/peptide biologics. The firm invests globally but has a strong presence in the United States, Canada, and Europe.

Logos Capital is a hedge fund manager based in San Francisco, founded in 2019, specializing in fundamental biotechnology investments. The firm combines in-house data analytics with scientific and clinical expertise to rigorously evaluate potential therapies and treatment platforms. It uses fundamental and sector-focused equity strategies and applies statistical modeling of clinical data to strengthen diligence and identify compelling opportunities with the aim of delivering uncorrelated returns. By integrating medical, scientific, and statistical perspectives, Logos Capital seeks to deepen its conviction in investment ideas and maintain disciplined risk management.

Founded in 1987, Canaan Partners is a global venture capital firm based in Menlo Park, California. With over $5 billion under management, the firm invests in early-stage technology and healthcare companies worldwide.